Treatment and prevention of venous thromboembolic complications: focus on sulodexide
- Authors: Rodionova I.V.1, Vinogradova M.V.1, Skvortsova E.M.1, Skvortsov V.V.1
-
Affiliations:
- Volgograd State Medical University, Ministry of Health of Russia
- Issue: Vol 35, No 4 (2024)
- Pages: 57-60
- Section: From Practice
- URL: https://journals.eco-vector.com/0236-3054/article/view/632157
- DOI: https://doi.org/10.29296/25877305-2024-04-11
- ID: 632157
Cite item
Abstract
Venous thromboembolic complications (VTEC) are a common pathology that includes pulmonary embolism and deep vein thrombosis of the lower extremities. Modern drug therapy for VTEC includes taking anticoagulants, which reduce the risk of VTEC recurrence to 1–2% of cases. The article discusses the drug sulodexide, which belongs to the class of heparinoids. Sulodexide is a relatively safe drug that has anti-inflammatory and antithrombotic effects, reducing the release of cytokines, chemokines and growth factors, as well as proteinases and degrading enzymes. When taken orally, there is no pharmacological interaction with substances aimed at treating vascular diseases, so it can be prescribed to patients with concomitant diseases.
Keywords
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
I. V. Rodionova
Volgograd State Medical University, Ministry of Health of Russia
Author for correspondence.
Email: vskvortsov1@ya.ru
Candidate of Medical Sciences
Russian Federation, VolgogradM. V. Vinogradova
Volgograd State Medical University, Ministry of Health of Russia
Email: vskvortsov1@ya.ru
Russian Federation, Volgograd
E. M. Skvortsova
Volgograd State Medical University, Ministry of Health of Russia
Email: vskvortsov1@ya.ru
Russian Federation, Volgograd
V. V. Skvortsov
Volgograd State Medical University, Ministry of Health of Russia
Email: vskvortsov1@ya.ru
ORCID iD: 0000-0002-2164-3537
MD, Professor
Russian Federation, VolgogradReferences
- Никулина Н.Н., Тереховская Ю.В. Эпидемиология тромбоэмболии легочной артерии в современном мире: анализ заболеваемости, смертности и проблем их изучения. Российский кардиологический журнал. 2019; 24 (6): 103–8 [Nikulina N.N., Terekhovskaya Yu.V. Epidemiology of pulmonary embolism in today’s context: analysis of incidence, mortality and problems of their study. Russian Journal of Cardiology. 2019; 24 (6): 103–8 (in Russ.)]. doi: 10.15829/1560-4071-2019-6-103-108
- Лобастов К.В., Навасардян А.Р., Счастливцев И.В. Вторичная профилактика венозных тромбоэмболических осложнений в реальной клинической практике по данным анкетирования врачей. Рациональная фармакотерапия в кардиологии. 2021; 17 (2): 376–85 [Lobastov K.V., Navasardyan A.R., Schastlivtsev I.V. Treatment and Secondary Prevention of Venous Thromboembolism in Real Clinical Practice Based on Health Care Professional Survey. Rational Pharmacotherapy in Cardiology. 2021; 17 (2): 376–85. (in Russ.)]. doi: 10.20996/1819-6446-2021-06-01
- Богачев В.Ю., Болдин Б.В., Дженина О.В. и др. Вторичная профилактика венозных тромбоэмболических осложнений. В фокусе – дабигатран. Амбулаторная хирургия. 2017; 3-4: 36–42 [Bogachev V., Boldin B.V., Djenina О., Lobanov V.N. Secondary prevention of venous thromboembolic complications. Focus on dabigatrane. Ambulatory Surgery (Russia). 2017; 3-4: 36–42 (in Russ.)].
- Стойко Ю.М., Карташева Е.Д. Выбор антикоагулянта у пациента с венозными тромбоэмболическими осложнениями. Амбулаторная хирургия. 2016; 1-2: 29–35 [Stoyko Yu.M., Kartasheva E.D. Choosing an anticoagulant for a patient with venous thromboembolic complications. Ambulatory Surgery (Russia). 2016; 1-2: 29–35 (in Russ.)].
- Линчак Р.М. Нюансы и алгоритмы антикоагулянтной терапии венозных тромбоэмболических осложнений на всех этапах лечения. Позиции апиксабана. Атмосфера. Новости кардиологии. 2020; 2: 26–36 [Linchak R.M. Details and Algorithms of Anticoagulant Therapy of Venous Thromboembolic Complications at All Stages of Treatment. Positions of Apixaban. Atmosfera. Novosti kardiologii. 2020; 2: 26–36 (in Russ.)].
- Veraldi N., Guerrini M., Urso E. et al. Fine structural characterization of sulodexide. J Pharm Biomed Anal. 2018; 156: 67–79. doi: 10.1016/j.jpba.2018.04.012
- Ligi D., Croce L., Mosti G. et al. Chronic venous insufficiency: transforming growth factor-beta isoforms and soluble endoglin concentration in different states of wound healing. Int J Mol Sci. 2017; 18: E2206. doi: 10.3390/ijms18102206
- Мясников Р.П., Куликова О.В., Харлап М.С. и др. Некомпактный миокард левого желудочка: вторичная профилактика тромбоэмболических осложнений. Кардиоваскулярная терапия и профилактика. 2017; 16 (1): 100–4 [Myasnikov R.P., Kulikova О.V., Kharlap М.S. et al. Non-compaction myocardium of the left ventricle: secondary prevention of thromboembolism. Cardiovascular Therapy and Prevention. 2017; 16 (1): 100–4 (in Russ.)]. doi: 10.15829/1728-8800-2017-1-100-104
- Zhang X., Sun D., Song J.W., et al. Endothelial cell dysfunction and glycocalyx – a viscious circle. Matrix Biol. 2018; 72: 421–31. doi: 10.1016/j.matbio.2018.01.026
- Поляков А.С., Тыренко В.В., Крюков Е.В. и др. Оптимальный выбор антикоагулянтной профилактики при неклапанной фибриляции предсердий в период пандемии COVID-19. Российский кардиологический журнал. 2021; 26 (8): 4607 [Polyakov A.S., Tyrenko V. V., Kryukov E.V. et al. Optimal choice of prophylactic anticoagulant therapy for nonvalvular atrial fibrillation in the context of COVID-19 pandemic. Russian Journal of Cardiology. 2021; 26 (8): 4607 (in Russ.)]. doi: 10.15829/1560-4071-2021-4607
- Kearon C., Akl E., Ornelas J. et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149 (2): 315–52. doi: 10.1016/j.chest.2015.11.026
- Ширинбек О. Фармакотерапия хронических заболеваний вен: возможности сулодексида. Амбулаторная хирургия. 2015; 1-2: 26–30 [Shirinbek O. Pharmacotherapy of chronic vein diseases: possibilities of sulodexide. Ambulatory Surgery (Russia). 2015; 1-2: 26–30 (in Russ.)].
- Воробьев П.А., Воробьев А.П., Краснова Л.С. и др. Систематический обзор по оценке медицинской технологии применения лекарственного препарата Вессел Дуэ ф для лечения тромботических заболеваний вен. Проблемы стандартизации в здравоохранении. 2016; 7-8: 61–6 [Vorobiev P.A., Vorobiev A.P., Krasnova L.S. et al. Systematic review on health technology assessment of the use of drugs vessel due f for treatment of thrombotic diseases of the veins. Problems of standardization in healthcare. 2016; 7-8: 61–6 (in Russ.)].
- Iafrati M.D. Medical therapies for chronic venous insufficiency. In book: Venous Ulcers (Second Edition). Akademic Press,2023; pp. 261–82. doi: 10.1016/B978-0-323-90610-4.00010-0
- Lasierra Cirujeda J., Coronel Granado P. A study on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis. Angiology. 2006; 57 (1): 53–64. doi: 10.1177/000331970605700108
- Coccheri S, Scondotto G, Agnelli G, et al. Randomized, double-blind, multicentre, placebo-controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost. 2002; 87 (6): 947–52.
Supplementary files
![](/img/style/loading.gif)